Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Connolly

Showing results (411-420 of 463) with videos related to

Pageof 47
Sort By:
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic TargetAlfredo Perales-Puchalt, Nikolaos Svoronos, Melanie R Rutkowski, et al.
The International Journal on Drug Policy|December 15, 2022
Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugsElizabeth J Austin, Alexander J Gojic, Elenore P Bhatraju, et al.
Nature Communications|June 23, 2026
Spatial analyses implicate high stromal tumour-infiltrating CD8<sup>+</sup> lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancerZak Kinsella, Chowdhury Arif Jahangir, Hannah Nyarkoah Nyarko, et al.
Drug and Alcohol Dependence Reports|January 23, 2024
Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugsJ I Tsui, A J Gojic, K A Pierce, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2022
Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axisDuygu Ozmadenci, Jayanth S Shankara Narayanan, Jacob Andrew, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 20, 2021
Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsyCristina R Reschke, Luiz F A Silva, Vamshidhar R Vangoor, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 2, 2023
Integrated analysis of transcriptomic and proteomic alterations in mouse models of ALS/FTD identify early metabolic adaptions with similarities to mitochondrial dysfunction disordersAnna Matveeva, Orla Watters, Ani Rukhadze, et al.
Cancer Research|June 19, 2021
CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer TumorigenesisAnni Laine, Srikar G Nagelli, Caroline Farrington, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2023
MicroRNA-335-5p suppresses voltage-gated sodium channel expression and may be a target for seizure controlMona Heiland, Niamh M C Connolly, Omar Mamad, et al.
Pageof 47

Showing results (411-420 of 463) with videos related to

Sort By:
Pageof 47
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic TargetAlfredo Perales-Puchalt, Nikolaos Svoronos, Melanie R Rutkowski, et al.
The International Journal on Drug Policy|December 15, 2022
Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugsElizabeth J Austin, Alexander J Gojic, Elenore P Bhatraju, et al.
Nature Communications|June 23, 2026
Spatial analyses implicate high stromal tumour-infiltrating CD8<sup>+</sup> lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancerZak Kinsella, Chowdhury Arif Jahangir, Hannah Nyarkoah Nyarko, et al.
Drug and Alcohol Dependence Reports|January 23, 2024
Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugsJ I Tsui, A J Gojic, K A Pierce, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2022
Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axisDuygu Ozmadenci, Jayanth S Shankara Narayanan, Jacob Andrew, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 20, 2021
Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsyCristina R Reschke, Luiz F A Silva, Vamshidhar R Vangoor, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 2, 2023
Integrated analysis of transcriptomic and proteomic alterations in mouse models of ALS/FTD identify early metabolic adaptions with similarities to mitochondrial dysfunction disordersAnna Matveeva, Orla Watters, Ani Rukhadze, et al.
Cancer Research|June 19, 2021
CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer TumorigenesisAnni Laine, Srikar G Nagelli, Caroline Farrington, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2023
MicroRNA-335-5p suppresses voltage-gated sodium channel expression and may be a target for seizure controlMona Heiland, Niamh M C Connolly, Omar Mamad, et al.
Pageof 47